Biofrontera (BFRI) Competitors

Biofrontera (NASDAQ:BFRI) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.

Which has preferable valuation and earnings, BFRI or TXMD?

TherapeuticsMD has lower revenue, but higher earnings than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$34.07M	0.12	-$20.13M	-$2.26	-0.32
TherapeuticsMD	$1.30M	12.42	-$10.28M	N/A	N/A

Do analysts recommend BFRI or TXMD?

Biofrontera currently has a consensus price target of $7.00, suggesting a potential upside of 853.68%. Given Biofrontera's stronger consensus rating and higher possible upside, research analysts clearly believe Biofrontera is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
TherapeuticsMD	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media prefer BFRI or TXMD?

In the previous week, Biofrontera had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 9 mentions for Biofrontera and 8 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.07 beat Biofrontera's score of -0.01 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is BFRI or TXMD more profitable?

Biofrontera has a net margin of -36.31% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-36.31%	-652.37%	-90.60%
TherapeuticsMD	-207.77%	-14.08%	-9.61%

Do institutionals & insiders have more ownership in BFRI or TXMD?

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.2% of Biofrontera shares are held by insiders. Comparatively, 2.3% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility and risk, BFRI or TXMD?

Biofrontera has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Does the MarketBeat Community favor BFRI or TXMD?

TherapeuticsMD received 378 more outperform votes than Biofrontera when rated by MarketBeat users. However, 66.67% of users gave Biofrontera an outperform vote while only 59.48% of users gave TherapeuticsMD an outperform vote.

Company	Underperform	Outperform
Biofrontera	Outperform Votes 8 66.67%	Underperform Votes 4 33.33%
TherapeuticsMD	Outperform Votes 386 59.48%	Underperform Votes 263 40.52%

Summary

TherapeuticsMD beats Biofrontera on 9 of the 16 factors compared between the two stocks.